Pregabalin Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/01/2023 
SmPC and PL 
To update sections 4.4 and 4.8 of the SmPC to implement 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
the wording related to the cases of abuse and dependence 
in patients without a history of substance disorder, 
following same assessment for Parent Product. Package 
leaflet has been updated accordingly. Minor editorial 
changes: DA, DE, EL, ES, ET, FI, FR, HR, HU, IT, LT, LV, 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
MT, NL, NO, PL, PT, RO. 
IB/0024 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/10/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0023 
Minor change in labelling or package leaflet not 
13/09/2022 
31/10/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0022/G 
This was an application for a group of variations. 
20/05/2022 
31/10/2022 
SmPC and PL 
To update Section 4.4 of the SmPC with warning about 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Severe cutaneous adverse reactions (SCARs) including 
Stevens-Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) and Section 4.8 of the SmPC to include 
“toxic epidermal necrolysis” with frequency “rare”. 
To update Sections 4.4 and 4.6 of the SmPC and Section 2 
of the PL with warning for women of childbearing 
potential/Contraception. 
IAIN/0021/G 
This was an application for a group of variations. 
06/04/2022 
31/10/2022 
Annex II and 
PL 
B.III.1.b.1 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for an AS from a new or an already 
approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
Page 3/11 
 
 
 
 
 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/01/2022 
31/10/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/11/2021 
31/10/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
T/0018 
Transfer of Marketing Authorisation 
24/09/2021 
03/11/2021 
SmPC, 
Labelling and 
PL 
IAIN/0017/G 
This was an application for a group of variations. 
10/05/2021 
03/11/2021 
Annex II and 
PL 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.7 - Administrative change - Deletion of 
manufacturing sites 
WS/2006 
This was an application for a variation following a 
14/01/2021 
03/11/2021 
SmPC and PL 
worksharing procedure according to Article 20 of 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commission Regulation (EC) No 1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/1268/G 
This was an application for a group of variations. 
17/07/2020 
n/a 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
R/0014 
Renewal of the marketing authorisation. 
30/01/2020 
03/04/2020 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Pregabalin Mylan in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
WS/1603 
This was an application for a variation following a 
11/07/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
N/0012 
Minor change in labelling or package leaflet not 
15/03/2019 
03/04/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IG/1013/G 
This was an application for a group of variations. 
19/12/2018 
n/a 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
T/0010 
Transfer of Marketing Authorisation 
25/07/2018 
10/09/2018 
SmPC, 
Labelling and 
PL 
IAIN/0009 
B.II.b.2.c.1 - Change to importer, batch release 
04/06/2018 
Annex II and 
arrangements and quality control testing of the FP - 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/03/2018 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0007/G 
This was an application for a group of variations. 
12/02/2018 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/01/2018 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/0769/G 
This was an application for a group of variations. 
10/05/2017 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
PL 
SmPC, 
Labelling and 
PL 
SmPC, 
Labelling and 
PL 
Page 8/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Page 9/11 
 
 
 
 
 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IB/0004/G 
This was an application for a group of variations. 
07/04/2017 
02/06/2017 
SmPC, 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
Labelling and 
PL 
Page 10/11 
 
 
 
 
 
 
 
 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
IG/0723 
A.5.b - Administrative change - Change in the name 
05/01/2017 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
WS/0859 
This was an application for a variation following a 
14/01/2016 
11/01/2017 
SmPC 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
storage conditions of the finished product - Other 
variation 
IG/0647 
C.I.8.a - Introduction of or changes to a summary of 
11/01/2016 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 11/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
